RESUMO
Investigou-se o perfil de 80 pacientes diabéticos tipo 2 (PDT2), constituído de homens (45%) e mulheres (55%) com média de idade de 62,8 ± 8,5 anos, usuários de insulina NPH fornecida pela Secretaria Municipal de Saúde de Maringá, PR, Brasil. Obteve-se informações por meio de um questionário e pela medida do índice de massa corporal (IMC). Verificou-se que: 1) 72% apresentavam obesidade ou sobrepeso; 2) 67,5% utilizavam antihipertensivos dos quais os inibidores da enzima conversora (ECA) e os bloqueadores dos receptores de angiotensina (BRA) representavam 84%; 3) O IMC foi similar em PDT2 usuários ou não de agentes antihipertensivos; 4) 46% além da insulina utilizavam antidiabéticos orais; 5) a dose de insulina (unidades. kg-1. dia-1) foi inferior (p< 0,05) em usuários de antihipertensivos, sugerindo existir uma correlação entre terapia antihipertensiva e o uso de menores doses de insulina. Este efeito ocorreria de maneira independente do IMC ou da simultânea a terapia com antidiabéticos orais.
The profile of 80 type-2 diabetic patients (T2DP), male (45%) and female (55%), with mean age 62.8 ± 8.5 years old, receiving NPH insulin from the municipal health department of Maringa city, PR, Brazil, was investigated. Information about each volunteer was obtained using a questionnaire and an evaluation of body mass index (BMI). It was verified that: 1) 72% showed obesity or overweight; 2) 67.5% used antihypertensive drugs in which angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) were the main antihypertensive drugs (84%); 3) The BMI was similar in the T2DP with hypertension or without hypertension; 4) 46%, in addition to insulin therapy, also used antidiabetic drugs; 5) The daily dose of insulin (units. kg-1. day-1) in the group which received antihypertensive therapy was lower (p< 0.05), suggesting the presence of a relationship between antihypertensive treatment and lower doses of insulin. In addition, this relationship would occur independently of the influence of BMI or the simultaneous treatment with oral antidiabetic drugs.